Arbutus Biopharma Corp (ABUS) Aksiya narxi va yangiliklar

Bosh sahifaABUS • NASDAQ

Arbutus Biopharma Corp

4,26 $

16-mar, 8:20:34 (GMT-4) · USD · NASDAQ · Ogohlantirish

AksiyalarAQSH qimmatli qogʻoziBosh shtabi: AQSH

Yopilish kursi

4,26 $

Yillik diapazon

2,71 $ - 5,10 $

Bozor kapitalizatsiyasi

819,30 mln USD

Oʻrtacha hajm

2,67 mln

Narx/foyda

Dividend daromadliligi

Asosiy maydon

NASDAQ

Bozor yangiliklari

Yahoo Finance

16 daqiqa oldin

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute Exclusive Manufacturing and Distribution Agreement with Initial $11 Million Commitment to Expand XOS Platform into India.

Fresno Bee

37 daqiqa oldin

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

SEALSQ Announces $125.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

Acadia Pharmaceuticals Rings the Opening Bell

ACAD

0,00%

Haqida

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

CEO

William H. Collier

Tashkil etilgan

2007

Bosh ofis

Warminster Township, Pennsilvaniya
Amerika Qo‘shma Shtatlari

Sayt

arbutusbio.com

Xodimlar soni